Relugolix for treating advanced hormone-sensitive prostate cancer

Relugolix is in clinical development for the treatment of adult males with advanced androgen-sensitive prostate cancer. Prostate cancer develops in the prostate (a small gland which is part of the male reproductive system). When the cancer spreads from the prostate to other parts of the body this is known as advanced prostate cancer. Androgen-sensitive prostate cancer needs androgens (male sex hormones) which are produced in the testis in order for the cancer to grow. Treating hormone-sensitive prostate cancer involves administering medicines which reduce the amount of androgens produced (androgen deprivation treatments) in patients.